News Search Results
Jan 27, 2026, 17:52 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Jan 27, 2026, 17:48 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Jan 27, 2026, 17:48 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Jan 27, 2026, 17:45 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Jan 27, 2026, 17:38 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Jan 27, 2026, 17:31 ET Pharma Conference Coverage Services: Real-Time Pharma Intelligence to Power Strategic Decision-Making
Conference Coverage: The fast pace of innovation in neurological diseases, such as Alzheimer's, Parkinson's, Schizophrenia, multiple sclerosis, and rare CNS disorders, makes it difficult for organizations to synthesize and interpret emerging data. DelveInsight's neurology conference coverage of the EAN
More news about: DelveInsight Business Research, LLP
Jan 27, 2026, 12:00 ET New indication in children from birth for Guerbet's half-dose GBCA, Elucirem™ (Gadopiclenol) approved by European Commission
blood-brain-barrier (BBB) and/or abnormal vascularity of:the brain, spine, and associated tissues of the central nervous system (CNS);the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system.For these indications, an MRI examination with
More news about: Guerbet
Jan 27, 2026, 08:46 ET The European Commission extended the Marketing Authorisation for Vueway® (gadopiclenol) in the European Union for use in pediatric patients under 2 years of age
54(8):475-484.Hao J, Pitrou C, Bourrinet P. A Comprehensive Overview of the Efficacy and Safety of Gadopiclenol: A New Contrast Agent for MRI of the CNS and Body. Invest Radiol 2024; 59(2):124-130.Kanal E, Maki JH, Schramm P, Marti-Bonmati L. Evolving Characteristics of Gadolinium-Based Contrast
More news about: Bracco Group
Jan 27, 2026, 02:00 ET The European Commission extended the Marketing Authorisation for Vueway® (gadopiclenol) in the European Union for use in pediatric patients under 2 years of age
54(8):475-484.Hao J, Pitrou C, Bourrinet P. A Comprehensive Overview of the Efficacy and Safety of Gadopiclenol: A New Contrast Agent for MRI of the CNS and Body. Invest Radiol 2024; 59(2):124-130.Kanal E, Maki JH, Schramm P, Marti-Bonmati L. Evolving Characteristics of Gadolinium-Based Contrast
More news about: Bracco Group
Jan 26, 2026, 09:30 ET Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery
Weinstein, CEO of Lunai Bioworks. "Our strategy is to build high-value, partner-ready programs that leverage our platform to address large, underpenetrated CNS markets."The program is supported by a Small Business Technology Transfer (STTR) grant from the National Institutes of Health (NIH) and is being
More news about: Lunai Bioworks Inc.
Jan 26, 2026, 08:30 ET Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
dyskinesia (TD). Inhibition of VMAT2 is expected to provide therapeutic benefit in TD, other hyperkinetic movement disorders, and potentially other CNS disorders where dopaminergic signaling is dysregulated.About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading
More news about: Neurocrine Biosciences, Inc.
Jan 23, 2026, 09:16 ET ATLEY AND PERCEPTIVE ANNOUNCE STRATEGIC COLLABORATION FOCUSED ON ASTATINE-211
translational solutions that bridge scientific innovation to early-phase clinical success. With deep expertise in radiochemistry, in-vivo imaging, oncology and CNS models, dosimetry, assay development, and radioligand therapy, Perceptive Discovery provides integrated workflows that generate high-quality, decision-ready
More news about: Perceptive Discovery
Jan 23, 2026, 08:30 ET Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor
stages. More importantly, with the ability to cross the blood-brain barrier and reach the central nervous system (CNS) directly, ISM8969 establishes its distinctive advantage against CNS disorders including Parkinson's Disease, apart from a balanced druggability profile and efficacy against inflammation
More news about: Insilico Medicine
Jan 22, 2026, 16:17 ET Cohen & Steers Reports Results for Fourth Quarter and Full‑Year Ended December 31, 2025
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported its results for the fourth quarter and year ended December 31, 2025. The earnings release along with the accompanying earnings presentation
More news about: Cohen & Steers, Inc.
Jan 22, 2026, 08:00 ET The Brain Aneurysm Foundation Highlights Recent Advances from its Research Grantees
including the Canadian Heart and Stroke Foundation, helped validate an approach to develop lipid nanoparticle mRNA (LNP-mRNA) medicines for a range of CNS disorders. Along with colleagues at the University of British Columbia, Dr. Bernier spun off CereCura Nanotherapeutics Inc., which focuses on neurodegenerative
More news about: Brain Aneurysm Foundation
Jan 22, 2026, 07:00 ET Corero Network Security Partners with Argentina's Auben Networks to Accelerate Latin American Expansion
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today announced a strategic partnership
More news about: Corero Network Security
Jan 22, 2026, 05:00 ET New Breast Cancer Therapy to Reduce Risk of Recurrence and Improve Disease-Free Survival Now Available in Thailand
87.7% for the placebo arm. An additional five-year sub-group analysis demonstrated a 42% reduction in risk of recurrence and 59% reduction in risk of CNS recurrence or death of any cause in women who were HR+ and who had commenced neratinib therapy within 12 months of completing treatment with trastuzumab.The
More news about: Specialised Therapeutics
Jan 20, 2026, 19:15 ET Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment
the two parties aim to accelerate the global advancement of ISM8969—an orally available, brain penetrant NLRP3 inhibitor for Central Nervous System (CNS) disorders. Under the terms of the agreement, Insilico grants Hygtia Therapeutics 50% worldwide rights to research, develop, register, manufacture,
More news about: Insilico Medicine
Jan 18, 2026, 20:00 ET D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002
cycling and suppressing oncogenic signaling. Preclinical studies show robust potency, complete KRAS G12C engagement at clinically relevant exposures, and CNS penetration capability. Elisrasib is currently being evaluated globally in a Phase 2 monotherapy and combination trial across KRAS G12C–mutant solid
More news about: D3 Bio
Jan 16, 2026, 08:00 ET Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
modalities such as ADCs, multi-specific antibodies and T-cell engagers (TCEs), covering oncology, autoimmune, metabolic and central nervous system (CNS) diseases. With the continued strengthening of its global commercialisation capabilities, international market revenue is expected to grow further, reinforcing
More news about: Henlius
Jan 15, 2026, 08:45 ET Announcing the release of NCC's FREE Monograph - Fetal Assessment and Safe Care During Labor!
Labor. This publication is available to all health care professionals free of charge. Authored by Kathleen Rice Simpson, PhD, RNC-OB, CNS-BC, FAAN this monograph was created to incorporate evidence-based labor management guidelines into maternal and fetal assessment during the intrapartum
More news about: National Certification Corporation
Jan 15, 2026, 07:04 ET Elevate Healthcare Marketing Appoints Industry Veteran Karen Beckert as Executive Vice President, Client Engagement and Customer Activation
major brand launches, significant omnichannel campaigns, and large cross-functional teams. Her category experience spans Dermatology, Rare Disease, CNS, Women's Health, Respiratory, Oncology, and Vaccines, with a proven ability to cultivate strong client relationships and guide teams in delivering strategic
More news about: Elevate Healthcare Marketing
Jan 15, 2026, 07:00 ET Brenig Therapeutics Announces Initiation of First-in-Human Study of BT-409, a Brain-Selective NLRP3 Inhibitor, and Provides Update on BT-267, its LRRK2 Program
program for BT-267, a LRRK2 inhibitor rationally designed to achieve robust CNS exposure while minimizing peripheral and systemic effects. Early clinical data demonstrate a favorable pharmacokinetic profile supporting sustained CNS exposure at levels predicted to exceed LRRK2 IC50 thresholds, with an encouraging
More news about: Brenig Therapeutics Inc
Jan 14, 2026, 16:20 ET Cohen & Steers, Inc. to Release Fourth Quarter and Full Year 2025 Results on January 22, 2026
NEW YORK, Jan. 14, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that it expects to release fourth quarter and full year 2025 results after the market closes on Thursday, January 22, 2026. The earnings release
More news about: Cohen & Steers, Inc.
Jan 14, 2026, 10:52 ET Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
presented enozertinib Phase 1b data demonstrating 67% ORR in first-line EGFR exon 20 mutations and 100% intracranial ORR in patients with measurable CNS disease. The company expects to report combination dose optimization data for rinzimetostat in 1Q 2026 and initiate its first global Phase 3 registrational
More news about: Equity Insider